Nihon Kohden

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Nihon Kohden sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 8 completed top decile by trial count

Nihon Kohden: 14 sponsored US clinical trials, none currently recruiting.

Nihon Kohden sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. The most-studied condition in this pipeline is Hypoxia, with 4 trials.

Top-decile sponsor footprint

Nihon Kohden ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

ACTIVE NOT RECRUITING

Pulse Oximeter Accuracy During Stable Hypoxia Plateaus

NCT07408388
ACTIVE NOT RECRUITING

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

NCT06689215
ACTIVE NOT RECRUITING

Determination of SpO2 and PR Accuracy Specifications at Rest (71Ag_Vital-0031)

NCT05297500
NOT YET RECRUITING

Hypoxia and Hemodilution Testing in Healthy Adult Volunteers

NCT07503171
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO19)

NCT05807477
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO18)

NCT05807464
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)

NCT05745662
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO16)

NCT05745675
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia During Motion

NCT04814342
COMPLETED

Accuracy of Pulse Oximeters With Profound Hypoxia at Rest

NCT04814823
TERMINATED

Capillary Refill Index with Rewarming

NCT04366310
TERMINATED

Comparison of Non-invasive Vs. Invasive Hemodynamic Measurements

NCT04180202
COMPLETED

Evaluation of Capillary Refill Index

NCT04144166
COMPLETED NA

Evaluation of Synthesized 18-Lead ECG in the Emergency Department

NCT03426436

Therapeutic Areas

Hypoxia 4
Chest Pain 1
Heart Failure, Congestive 1

How the Nihon Kohden archive is shaped

14 indexed studies, none listed as recruiting (0% open); 8 completed (57%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Hypoxia (4 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nihon Kohden: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Nihon Kohden sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Nihon Kohden3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Nihon Kohden sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nihon Kohden sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nihon Kohden page

14 registered trials is a research-attention snapshot, not an endorsement of Nihon Kohden or any single study.

  • None of Nihon Kohden's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hypoxia is the condition Nihon Kohden studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoxia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Nihon Kohden pipeline card: 14 registered trials from official public datasets.Report a data error.